MedTrace Logo

A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA

NCT04918862 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2021-06-21

No results posted yet for this study

Summary

Investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic surgeries under general anesthesia to prevent postoperative nausea and vomiting

Conditions

  • 1mg Vs 3 mg of Granisetron

Interventions

DRUG

Granisetron

210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery

Sponsors & Collaborators

  • Mohamed Yousry Mohamed

    collaborator UNKNOWN

  • Tamer Fayez Safan

    collaborator UNKNOWN

  • Tamer Mohamed Khair

    collaborator UNKNOWN

  • Mohamed, Ahmed A., M.D.

    collaborator INDIV

  • Islam Mohamed Sayed

    collaborator UNKNOWN

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed A Mohamed, M.D · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2021-05-09
Completion
2021-05-18

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04918862 on ClinicalTrials.gov